fda reconsiders tirzepatide fda changes to tirzepatide Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage-bsmoothhr FDA Allows Compounded Tirzepatide During

Merck and others are developing GLP-1s (MK-8521, orforglipron licensing, etc.), but as of 2026 none have announced capacity builds because their products are not yet commercial

BPC-157 is a synthetic pentadecapeptide connected to body-protective-compound literature

The biggest developments in medical weight loss include: Oral GLP-1 weight-loss therapy arrived in the US

When calories are restricted, adequate protein becomes essential to maintain muscle, says Dr

It is well known that malonyl-CoA is the key regulator of LCFA oxidation in the heart because it is the physiological and potent inhibitor of CPT I which transports LCFA from cytoplasm into mitochondria [42,43,44,45]

1 Introduction Global food security faces unprecedented challenges, as the world population is projected to reach 10 billion by 2050, with nearly two billion people currently suffering from nutrient deficiencies and approximately eight hundred million experiencing chronic hunger